RECTOGESIC 4 MG/G RECTAL OINTMENT
Rectogesic 4 mg/g Rectal Ointment is indicated in adults for relief of pain associated with chronic anal fissure.
Route of administration: rectal use
A finger covering, such as cling film or a finger cot, may be placed on the finger to be used to apply the ointment. (Finger cots to be obtained separately from local pharmacy or surgical supplies retailer or cling film from local store.) The finger is placed along side a 2.5cm dosing line which is provided on the outside carton in which Rectogesic is supplied, and a strip of ointment the length of the line is expressed onto the end of the finger by gently squeezing the tube. The amount of ointment expressed is approximately 375 mg (1.5 mg GTN). The covered finger is then gently inserted into the anal canal to the distal interphalangeal joint of the finger and applied circumferentially to the anal canal.
The dose delivered from the 4 mg/g ointment is 1.5 mg glyceryl trinitrate. The dose is to be applied intra-anally every twelve hours. Treatment may be continued until the pain abates, up to a maximum of 8 weeks.
Rectogesic should be used following conservative treatment failure for acute symptoms of anal fissure.
Elderly (over 65 years):
No specific information concerning the usage of Rectogesic in the elderly is available
Patients with Hepatic or Renal Impairment
No specific information concerning the usage of Rectogesic in patients with hepatic or renal impairment is available
Children and Adolescents:
Rectogesic is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy.
The risk/benefit ratio of Rectogesic has to be established on an individual basis. In some patients, following treatment with Rectogesic, severe headache can occur. In some cases re-evaluation of the correct dosing is suggested. In patients where the risk benefit ratio is deemed to be negative, treatment with Rectogesic should be withdrawn under the guidance of a physician and other therapeutic or surgical interventions should be initiated.
Rectogesic should be used with caution in patients who have severe hepatic or renal disease.
Excessive hypotension, especially for prolonged periods of time, must be avoided because of possible deleterious effects on the brain, heart, liver and kidney from poor perfusion and the attendant risk of ischaemia, thrombosis and altered function of these organs. Patients should be advised to change position slowly when changing from lying or sitting to upright to minimize postural hypotension. This advice is particularly important for those patients with low blood volume and under diuretic treatment. Paradoxical bradycardia and increased angina pectoris may accompany glyceryl trinitrate-induced hypotension. The elderly may be more susceptible to the development of postural hypotension, particularly on sudden rising. No specific information concerning the usage of Rectogesic in the elderly is available.
Alcohol may enhance the hypotensive effects of glyceryl trinitrate.
If the physician elects to use glyceryl trinitrate ointment for patients with cardiac disorders e.g. acute myocardial infarction or congestive heart failure, careful clinical and haemodynamic monitoring must be used to avoid the potential hazards of hypotension and tachycardia.
If bleeding associated with haemorrhoids increases, treatment should be stopped.
This formulation contains propylene glycol and lanolin which may cause skin irritations and skin reactions (e.g. contact dermatitis).
If anal pain persists, differential diagnosis may be required to exclude other causes of the pain.
Glyceryl trinitrate can interfere with the measurement of catecholamines and vanilmandelic acid in urine as it increases the excretion of these substances.
Concomitant treatment with a number of other medicinal products should be handled with caution.